Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac’s Q1 Doubles Its Year-Earlier Results

publication date: May 16, 2008

Sinovac Biotech Ltd. reported a very strong first quarter, maintaining the successes that, across the board, China-based biopharmas have been able to announce for early 2008. In Sinovac’s case, Q1 revenues were more than twice those of the year-earlier quarter. The company said it generated $8.9 million in sales, an increase of 123%. Net income was up 106% at $1.6 million, or 4 cents per share, fully diluted.  The company said that its revenue increases were driven by Healive®, Sinovac’s Hepatitis A vaccine and its lead product. More details...

Stock Symbol: (AMEX: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital